Pica can be a life-threatening condition. An investigation examines whether children with autism spectrum disorder and other developmental disorders are at greater risk of having it.
Case reports have shown that some children with either intellectual disability or autism spectrum have pica. However, there has been little study on how prevalent pica is in this population. An investigation in Pediatrics looked at pica in children, both with and without autism spectrum disorder, who were aged 30 to 68 months.1
The researchers used a sample from the Study to Explore Early Development, which is a multisite case-control study. The sample included children with autism spectrum disorder (n = 1426), children with other types of developmental disabilities (n = 1735), and general population-based controls (n = 1578). The autism spectrum disorder group was further divided by whether the child had an intellectual disability; the other developmental disorder group was divided by whether the child had an intellectual disability or some autism spectrum disorder characteristics. Questionnaires and assessments were used to define study groups, subgroups, and pica.
They found that the prevalence of pica among the population control participants was 3.5% and much higher in the other groups, occurring in 23.3% of children with autism spectrum disorder and 8.4% in the children with other developmental disorders. Additionally, the prevalence of pica was also increased in most of the subgroups:
The researchers noted, however, that pica prevalence was not higher in children who had a developmental disability but did not have an intellectual disability or autism spectrum disorder characteristics. The difference in prevalence remained even after adjusting (adjusted prevalence ratio range 1.9–8.0, all P <.05).
Reference
1. Fields V, Soke G, Reynolds A, et al. Pica, autism, and other disabilities. Pediatrics. January 6, 2021. Epub ahead of print. doi:10.1542/peds.2020-0462
Yamo enrolls final patient of phase 2 study of L1-79 to treat symptoms of ASD
November 29th 2023Yamo Pharmaceuticals has initiated a phase 3 readiness program for L1-79, following the enrollment of its final patient in a phase 2 study evaluating the autism spectrum disorder (ASD) treatment for patients aged 2 to 21 years.
Genetic Testing for Autism: What Can Be Done, How Helpful Is It?
January 26th 2011In this podcast, Dr John Harrington of Eastern Virginia Medical School and Children’s Hospital of The King’s Daughters, and Dr Michael Paul, CEO and Rena Vanzo, Genetic Counselor of Lineagen-provider of a new integrated genetic testing and counseling service FirstStepDx-discuss the diagnosis of autism and genetic testing for autism.
Discussing software that helps track progress after an autism diagnosis
October 27th 2023In this interview with Contemporary Pediatrics®, Lauren Lanzon, MSW, MA, BCBA, clinical trainer, Carolina Behavioral Innovations, explains how technology and software is helping families following an autism diagnosis in their child.
Paternal depression associated with adverse childhood experiences in children
October 21st 2023In this Q&A, Kristine H. Schmitz, MD, explains her team's recent research on paternal depression and adverse childhood experiences during the 2023 American Academy of Pediatrics National Conference & Exhibition.
Exome sequencing should be used for diagnosing cerebral palsy
October 13th 2023A systematic review and meta-analysis found that such sequencing indeed has an equivalent high genetic diagnostic yield in cerebral palsy, which supports including this neurodevelopmental disorder among those for which diagnostic exome sequencing should be used.
Is ADHD associated with shorter-than-expected height?
October 10th 2023To assess the role of familial factors, investigators analyzed data for a family-based group created from another Swedish national register that included 833,172 individuals without ADHD with different levels of relatedness to the individuals with ADHD and a group of matched controls.